Ultragenyx Pharmaceutical (RARE) Operating Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Operating Expenses data on file, last reported at $305.0 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $305.0 million, up 8.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 11.5% YoY), and the FY2025 annual result was $1.2 billion, up 10.22% from the prior year.
• Operating Expenses declined to $305.0 million in Q1 2026 per RARE's latest filing, from $320.6 million in the prior quarter.
• Over five years, Operating Expenses peaked at $330.8 million in Q3 2025 and troughed at $216.6 million in Q1 2022.
• A 5-year average of $272.0 million and a median of $271.5 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses surged 84.15% in 2022, then retreated 23.0% in 2023.
• A 5-year view of Operating Expenses shows it stood at $249.0 million in 2022, then rose by 0.0% to $249.0 million in 2023, then increased by 15.25% to $287.0 million in 2024, then climbed by 11.71% to $320.6 million in 2025, then dropped by 4.85% to $305.0 million in 2026.
• Business Quant data shows RARE's Operating Expenses at $305.0 million in Q1 2026, $320.6 million in Q4 2025, and $330.8 million in Q3 2025.